Avid Bioservices, Inc.
CDMO
NASDAQ
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 33.48M | 40.17M | 42.98M | 33.82M | 25.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.48M | 40.17M | 42.98M | 33.82M | 25.40M |
| Cost of Revenue | 35.53M | 34.46M | 37.48M | 31.43M | 30.06M |
| Gross Profit | -2.05M | 5.71M | 5.50M | 2.38M | -4.67M |
| SG&A Expenses | 10.59M | 8.17M | 6.79M | 6.38M | 6.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.11M | 42.63M | 44.27M | 37.81M | 36.62M |
| Operating Income | -12.63M | -2.46M | -1.29M | -4.00M | -11.22M |
| Income Before Tax | -17.41M | -5.53M | -5.23M | -7.06M | -11.91M |
| Income Tax Expenses | -- | -- | 117.87M | -1.05M | -2.39M |
| Earnings from Continuing Operations | -17.41M | -5.53M | -123.10M | -6.01M | -9.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.41M | -5.53M | -123.10M | -6.01M | -9.52M |
| EBIT | -12.63M | -2.46M | -1.29M | -4.00M | -11.22M |
| EBITDA | -8.66M | 368.00K | 1.57M | -1.18M | -8.44M |
| EPS Basic | -0.27 | -0.09 | -1.94 | -0.09 | -0.15 |
| Normalized Basic EPS | -0.17 | -0.05 | -0.03 | -0.07 | -0.12 |
| EPS Diluted | -0.27 | -0.09 | -1.94 | -0.09 | -0.15 |
| Normalized Diluted EPS | -0.17 | -0.05 | -0.03 | -0.07 | -0.12 |
| Average Basic Shares Outstanding | 63.84M | 63.64M | 63.50M | 63.32M | 63.15M |
| Average Diluted Shares Outstanding | 63.84M | 63.64M | 63.50M | 63.32M | 63.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
